Publikationen

1.  Originalarbeiten

Treeck O, Strunck E and Vollmer G (1998) A novel basement-membrane induced gene identified in the human endometrial adenocarcinoma cell line HEC1B. FEBS Letters425(3), 426-430

Treeck O, Odani T, Itoh N, Imai H, Fujita S, Kohroki J, Nakanishi T, Diedrich K, Ortmann O, Tanaka K and Vollmer G (2002) Detection of increased icb-1 transcript levels in maturing HL-60 cells: a novel marker for granulocytic and monocytic in vitro differentiation. Leukemia Research 26(8), 765-769

Treeck O, Diedrich K, Ortmann O (2002) Effekte von Kinase-Inhibitoren auf die Östradiolwirkung in der endometrialen Adenokarzinomzelllinie Ishikawa. Geburtshilfe und Frauenheilkunde 62, 877-881

Treeck O, Diedrich K, Ortmann O (2003) The activation of an extracellular signal-regulated kinase by estradiol interferes with the effects of trastuzumab on HER2 signaling in endometrial adenocarcinoma cell lines. European Journal of Cancer 39(9), 1302-9

Treeck O, Weber A, Boester M, Porz S, Frey N, Diedrich K, Ortmann O (2003) H-ras dependent estrogenic effects of epidermal growth factor in the estrogen-independent breast cancer cell line MDA-MB-231. Breast Cancer Research and Treatment 80(2), 155-162

Treeck O, Zhou R, Diedrich K, Ortmann O (2004) Tamoxifen long-term treatment in vitro alters the apoptotic response of MCF-7 breast cancer cells. Anti-Cancer Drugs 15(8), 787-93

Chen D, Hackl W, Ortmann O, Treeck O (2004) Effects of a combination of exemestane and paclitaxel on human tumor cells in vitro. Anti-Cancer Drugs 15(1), 55-61

Treeck O, Kindzorra I, Pauser K, Treeck L, Ortmann O (2005) Expression of icb-1 gene is interferon-gamma inducible in breast and ovarian cancer cell lines and affects the IFNgresponse of SK-OV-3 ovarian cancer cells. Cytokine 32(4), 137-142

Zhou R*, Treeck O*, Horn F, Ortmann O (2005) (*Äquivalenter Beitrag) Effects of prolonged tamoxifen treatment on receptor expression and apoptosis of ovarian cancer cells. Gynecologic Oncology 96(3), 678-683

Treeck O, Haldar C, Ortmann O (2006) Antiestrogens modulate MT1 melatoninreceptor expression in breast and ovarian cancer cell lines. Oncology Reports15(1), 231-236

Treeck O, Wackwitz B, Hauser U, Ortmann O (2006) Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecologic Oncology 102(2), 292-299

Weiss JM, Polack S, Treeck O, Diedrich K, Ortmann O (2006) Regulation of GnRH I receptor gene expression by the GnRH agonist triptorelin, estradiol, and progesterone in the gonadotroph-derived cell line alphaT3-1. Endocrine30(1):139-44

Treeck O, Pfeiler G, Horn F, Federhofer B, Houlihan H, Vollmer A, Ortmann O (2007) Novel estrogen receptor beta transcript variants identified in human breast cancer cells affect cell growth and apoptosis of COS-1 cells. Molecular and Cellular Endocrinology 264,50-60

Weiss JM, Huller H, Polack S, Friedrich M, Diedrich K, Treeck O, Pfeiler G, Ortmann O (2007) Estradiol differentially modulates the exocytotic proteins SNAP-25 and munc-18 in pituitary gonadotrophs. Journal of Molecular Endocrinology 38(2):305-14

Pfeiler G, Lattrich C, Horn F, Klappenberger S, Ortmann O, Treeck O(2007) Apoptotic effects of signal transduction inhibitors on human tumor cells with different PTEN expression. Oncology Reports 18(5),1305-1309

Treeck O, Pfeiler G, Mitter D, Lattrich C, Piendl G, Ortmann O (2007) Estrogen receptor beta 1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells. Journal of Endocrinology 193(3), 421-433

Treeck O, Juhasz-Boess I, Lattrich C, Horn F, Goerse R, Ortmann O (2008) Effects of exon-deleted estrogen receptor beta transcript variants on growth, apoptosis and gene expression of human breast cancer cell lines. Breast Cancer Research and Treatment 110(3), 507-520

Bollmann J, Ortmann O, Treeck O (2008) Expression of differentiation-associated gene icb-1 is estrogen-responsive in ovarian and breast cancer cell lines. Journal of Steroid Biochemistry and Molecular Biology 109(1-2), 16-21

Pfeiler GH, Buechler C, Neumeier M, Schäffler A, Schmitz G, Ortmann O, Treeck O (2008) Adiponectin effects on human breast cancer cells are dependent on 17-beta estradiol. Oncology Reports 19(3):787-93

Lattrich C, Juhasz-Boess I, Ortmann O, Treeck O (2008) Detection of an elevated HER2 expression in MCF-7 breast cancer cells overexpressing estrogen receptor beta1. Oncology Reports 19(3):811-7

Treeck O, Lattrich C, Juhasz-Boess I, Buchholz S, Pfeiler G, Ortmann O (2008)
Adiponectin differentially affects gene expression in human mammary epithelial
and breast cancer cells. Br J Cancer. 99(8):1246-50

Springwald A, Lattrich C, Seitz S, Ortmann O, Treeck O (2009) Single nucleotide
polymorphisms in human gene icb-1 and breast cancer susceptibility. Cancer
Invest. 69-72

Pfeiler G, Treeck O, Wenzel G, Goerse R, Hartmann A, Schmitz G, Ortmann O (2009)Correlation of body mass index and menopausal status with the intra-tumoral
estrogen system in invasive breast cancer. Gynecol Endocrinol. 25(3):183-7.

Treeck O, Elemenler E, Kriener C, Horn F, Springwald A, Hartmann A, Ortmann O (2009)Polymorphisms in the promoter region of ESR2 gene and breast cancer
susceptibility. J Steroid Biochem Mol Biol. 114(3-5):207-11

Pfeiler G, Treeck O, Wenzel G, Goerse R, Hartmann A, Schmitz G, Ortmann O (2009)
Influence of insulin resistance on adiponectin receptor expression in breast
cancer. Maturitas. 63(3):253-6

Fischer C, Juhasz-Boess I, Lattrich C, Ortmann O, Treeck O (2009) Estrogen receptor
beta gene polymorphisms and susceptibility to uterine fibroids. Gynecol
Endocrinol. 28:1-6

Treeck O, Lattrich C, Springwald A, Ortmann O (2009) Estrogen receptor beta exerts
growth-inhibitory effects on human mammary epithelial cells. Breast Cancer Res
Treat. 2009 May 12. PubMed PMID: 19434490.

Giess M, Lattrich C, Springwald A, Goerse R, Ortmann O, Treeck O (2009) GPR30 gene
polymorphisms are associated with progesterone receptor status and
histopathological characteristics of breast cancer patients. J Steroid Biochem
Mol Biol. PubMed PMID: 19744559.

2. Übersichtsarbeiten

Treeck O, Diedrich K, Ortmann O (2003) Neue Perspektiven in der endokrinen Therapie gynäkologischer Malignome. Der Gynäkologe 36(2), 117-120

Treeck O,Bohnert N, Siggel C, Diedrich K, Ortmann O (2003) Einfluss der zellulären Östradiolantwort auf die therapeutische Inhibition von Wachstumsfaktor-Signalwegen. Zentralblatt für Gynäkologie 125(2), 53-56

Treeck O, Diedrich K, Ortmann O (2003) Interaktionen zwischen Östrogenrezeptor- und Rezeptor-Tyrosinkinase- Signaltransduktion: Implikationen für die Therapie des Mammakarzinoms. Geburtshilfe und Frauenheilkunde 63, 1225-1232

Babilas K, Treeck O, Ortmann O (2004) Hormonersatztherapie und gynäkologische Malignome. Medizinische Welt 1-2, 1-4

Treeck O, Horn F, Ortmann O (2004) Endokrine Resistenzmechanismen - Schwerpunkt Mammakarzinom. GynSpectrum 3, 13-16

Treeck O, Diedrich K, Ortmann O (2004) Interaktionen zwischen Östrogenrezeptor- und Rezeptor-Tyrosinkinase- Signaltransduktion. Tumordiagnose und Therapie 25, 35-42

Mitter D, Ortmann O, Treeck O (2005) Östrogenrezeptor-β-Isoformen - Funktionen und klinische Bedeutung bei Brustkrebs. Zentralblattfür Gynäkologie 127, 28-34

Pfeiler GH, Lattrich C, Schambeck C, Langmann T, Treeck O , Ortmann O (2006) Metabolismus und Mammakarzinom. Geburtshilfe und Frauenheilkunde 66, 841-851

J uhasz-Böss I, Treeck O , Malik E, Ortmann O (2006) Aromatasehemmer in der Therapie der Endometriose. Gynäkologische Endokrinologie 4, 174-180

Sanders L,Görse R, Treeck O , Ortmann O (2007) Benigne Brusterkrankungen - Ätiologie und Klinik. Geburtshilfe und Frauenheilkunde 67, 321-328

3. Buchkapitel

Treeck O (2008) Einführung in die Endokrinologie. In: Klinische Endokrinologie für Frauenärzte. Hrsg.: FA Leidenberger, T Strowitzki, O Ortmann. Heidelberg: Springer Medizin Verlag

Treeck O und Ortmann O (2008) Endokrinium und Tumorwachstum. In: Klinische Endokrinologie für Frauenärzte. Hrsg.: FA Leidenberger, T Strowitzki, O Ortmann. Heidelberg: Springer Medizin Verlag

© 2002-2012 Caritas-Krankenhaus St. Josef Regensburg - Impressum